Policy
In a Cabinet meeting, Health Secretary Robert F. Kennedy Jr. said the website could go live “probably in the next 10 days,” but an exact launch date remains unclear.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
TFS International is thrilled with the announcement that Lecigon®, a new therapeutic system for symptomatic treatment of Advanced Parkinson’s Disease (APD), has been granted marketing authorization in Sweden.
FDA issued a Complete Response letter to Acacia Pharma on Friday 5 October
Application Seeks Accelerated Approval for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma
Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired TG Therapeutics, Inc. securities from June 4, 2018 through September 25, 2018
pceth Biopharma GmbH congratulates its partner bluebird bio on the acceptance and validation of its market authorization application by the European Medicines Agency (EMA).
Swiss pharma giant Novartis could be on its way to securing regulatory approval for its secondary progressive multiple sclerosis (SPMS) treatment siponimod.
Opioid manufacturers have been the target of thousands of lawsuits from state and local governments seeking to reclaim funds that have been spent on addressing treatment for opioid abuse and overdoses.
Opioids have shown tremendous efficacy in pain management. At the same time, the dangers of the addiction to the medication have become well-known in recent years as an epidemic has swept across the United States.
A former employee in Biogen’s IT department, filed a lawsuit in federal court last month claiming the company discriminated against him because of his Parkinson’s disease.
Orchard Therapeutics, with locations in Boston and London, UK, received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for OTL-300, a lentiviral gene therapy for transfusion-dependent beta-thalassemia (TDBT).